Revolutionary Weight Loss Drug Targets NK2R to Combat Obesity and Diabetes

Researchers at the University of Copenhagen have discovered a new method for weight loss that reduces appetite, increases energy use, and improves insulin sensitivity. This new approach may provide effective treatment options for obesity and type 2 diabetes without common side effects.

Many people use existing weight-loss drugs based on the incretin hormone GLP-1. While these drugs help with weight and can improve kidney function, they often cause side effects like nausea and vomiting. Additionally, they are less effective for those struggling with both obesity and type 2 diabetes, affecting over 380 million people globally.

In a study published in Nature, scientists introduced a drug that activates the Neurokinin 2 Receptor (NK2R). This activation reduces appetite and increases calorie burning without causing nausea or muscle loss. The results were encouraging; not only did the NK2R activation lower appetite, but it also improved energy expenditure.

The researchers tested this method in mice first, then in non-human primates with obesity and type 2 diabetes. They found that activating NK2R successfully reduced body weight and reversed diabetes by improving insulin sensitivity and decreasing blood sugar levels, triglycerides, and cholesterol.

PhD student Frederike Sass stated that their findings show promise for translating this treatment to humans. The research aims to provide better and more accessible drug options for nearly 400 million people worldwide living with obesity and type 2 diabetes.

The University of Copenhagen has filed patents for targeting NK2R and has already facilitated the founding of several biotech companies focused on this research. In 2023, Embark Biotech was acquired by Novo Nordisk to further develop innovative treatments for related health conditions.